Phase II study of vindesine in patients with non-small cell lung cancer.

Abstract

A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). There were 13 and 8 patients with and without prior chemotherapy, respectively. VDS was administered at a weekly iv dose of 3 mg/m2. Partial response was observed in two of 15 adenocarcinomas and one of 2 adenosquamous cell carcinomas, and the overall response rate was 14.3% (3/21). Myelosuppression, especially leukopenia, was the most common dose-limiting side effect. Neurotoxicity was also a common side effect but the degree was mild. It was concluded that VDS at a dose of 3 mg/m2 every week seems to be active against NSCLC.

• Authors: J Fujita, N Saijo, K Eguchi, T Shinkai, K Tominaga, Y Sasaki, H Futami, M Sakurai, J Ishihara, H Takahashi
• Journal: Japanese journal of cancer research : Gann (Jpn J Cancer Res) Vol. 76 Issue 9 Pg. 902-5 (Sep 1985) ISSN: 0910-5050 [Print] Japan
• PMID: 2997097 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Vindesine

Topics

• Adenocarcinoma (drug therapy)
• Aged
• Carcinoma, Small Cell (drug therapy)
• Carcinoma, Squamous Cell (drug therapy)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Neoplasm Metastasis
• Time Factors
• Vindesine (adverse effects, therapeutic use)